News
2010 | 2009 | 2008 | 2007 | 2006
London, 22 December 2008
ImmuPharma receives further installment of grant for developing cancer drug
ImmuPharma PLC (LSE:IMM), ("ImmuPharma or the "Company") the specialist drug discovery and development company, is pleased to announce that it has been awarded a further installment of a grant (see press release dated 12 November 2008) from French government organisations bringing the total received to €1.15m. The grants are to be used for the development of ImmuPharma's cancer drug candidate IPP-204106.
London, 25 November 2008
Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
FRAZER, Pa., and London, UK (November 25, 2008) -- Cephalon, Inc. (Nasdaq: CEPH) and ImmuPharma PLC (LSE:IMM), a European pharmaceutical company, today announced that the companies have signed an Option Agreement providing Cephalon with an option to obtain an exclusive, worldwide license to the investigational medication Lupuzor™ for the treatment of Systemic Lupus Erythematosus. ImmuPharma is now conducting a large Phase IIb study of Lupuzor in patients in Europe and Latin America.
Under the terms of the option agreement, Cephalon will pay ImmuPharma a $15 million upfront option payment. If the Phase IIb studies are successful and if the option is exercised then the parties enter into an exclusive worldwide license agreement and ImmuPharma will receive a one-time license fee, milestone payments upon the achievement of regulatory milestones and royalties on commercial sales of Lupuzor. The various milestone payments which include sales milestones may total up to $500 million. Upon exercise of the option, Cephalon will assume all expenses for Phase III studies and subsequent commercialization of the product.
London, 12 November 2008
ImmuPharma awarded grant for developing cancer drug
ImmuPharma PLC (LSE:IMM), ("ImmuPharma or the "Company") the specialist drug discovery and development company, is pleased to announce that it has been awarded €0.9m as one of the two grants it has been anticipating from French government organisations. The grants are to be used for the development of ImmuPharma's cancer drug candidate IPP-204106.
London, 21 October 2008
LupuzorTM patents allowed in US and approved in Japan, Australia - other countries expected to follow
ImmuPharma PLC (LSE:IMM), ("ImmuPharma or the "Company") the specialist drug discovery and development company, is pleased to announce that the LupuzorTM patent was approved in Japan and Australia and received notice of allowance from in the US Patent Office. LupuzorTM is ImmuPharma's lead drug compound for the potential treatment of Lupus, a chronic, life-threatening autoimmune disease.
In addition, the mechanism of action of LupuzorTM has been identified by researchers working with ImmuPharma at the Centre National de la Recherche Scientifique in Strasbourg. LupuzorTM has shown that it modulates, through a unique mechanism, a specific subset of CD4 T cells which play a critical role in the physiopathology of Lupus.
London, 17 October 2008
ImmuPharma PLC (the "Company")
Additional Listing and Total Voting Rights
Following the receipt of notices of exercise of options, application has been made to the London Stock Exchange for the admission of 132,000 new ordinary shares to trading on AIM.
London, 25 September 2008
Interim results announcement for the
six months ended 30
June 2008
ImmuPharma plc (LSE:IMM), the specialist discovery and development pharmaceutical company is pleased to announce its interim results for the six months ended 30 June 2008.
INTERIM HIGHLIGHTS
■ First patients dosed in Phase IIb trial of our lead asset for lupus, IPP-201101, during the period under review with subsequent ongoing progress being made and headline efficacy data expected later in the year;
■ Successfully obtained LUPUZOR™ trademark for IPP-201101, our lead asset for lupus
■ Encouraging pre-clinical data from new portfolio candidate, IPP-204106 for multiple forms of cancer
■ Raised £2.7m in a share placing from UK and Swiss institutional investors;
■ In addition to our discovery pipeline, our portfolio now
includes five drug candidates:
□ IPP-201101, LUPUZOR™ for the treatment of
lupus
□ IPP-204106, for the treatment of cancer
□ IPP-201007, for the treatment of
inflammation
□ IPP-102199, for the treatment of moderate
and severe pain
□ IPP-203101, for the treatment of MRSA and
other hospital-
acquired infections
Commenting on the progress to date and the outlook for ImmuPharma, Dimitri Dimitriou, Chief Executive Officer, said: "The first half of 2008 has been an exciting time for ImmuPharma with the addition of IPP-204106 for the treatment of cancer, the first patients being dosed with LUPUZOR™ and ongoing progress being made in a Phase IIb trial that is anticipated to report headline efficacy data later in the year, and a successful share placement raising £2.7m. The Company continues to develop its assets and discussions with potential partners."
London, 10 July 2008
ImmuPharma raises additional £1.1 million (CHF 2.2 million) to advance development programmes
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has raised additional proceeds of approximately £1.1 million (£1.07 million net of expenses) or approximately CHF 2.2 million principally from institutional investors based in Switzerland through a placing of 1,876,000 new ordinary shares of 10p each in the Company at a price of 60 pence per share. This represents the final tranche of the placing announced by the Company on 2 July 2008 (the “Placing”) and is subject to the same terms and conditions, as set out in the Appendix to this announcement.
London, 2 July 2008
Long term toxicology studies confirmed the safety of LupuzorTM
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today LupuzorTM its treatment for Lupus, a chronic, life-threatening autoimmune disease, completed the first leg of the mandatory long term toxicology study package. International regulations require two long term toxicology studies (6 and 9 months) for drug products intended to be use chronically. ImmuPharma reports that the first study has been completed and that there was no clinical or laboratory findings suggesting any safety issues. Further, an interim analysis of the second study supported these findings. These studies were requirements from The FDA (Food and Drug Administration) in the US prior to initiating ImmuPharma's Phase III programme.
London, 2 July 2008
ImmuPharma raises £1.6 million to advance development programmes
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has raised approximately £1.6 million (approximately £1.5 million net of expenses) principally from institutional investors through a placing of 2,697,034 new ordinary shares of 10p each in the Company at a price of 60 pence per share subject to the terms and conditions set out in the Appendix to this announcement (the "Placing").
London, 20 May 2008
ImmuPharma’s cancer drug candidate IPP- 204106 shows complete response to tumours in multiple human cancer cell lines
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today pre-clinical data on its new cancer drug, IPP-204106. Data on ImmuPharma’s anti-cancer nucleolin antagonist (“Nucant”) peptide programme, IPP-204106 have been obtained confirming the ability of the compounds to effectively control and stop the growth of a large panel of human cancer cell lines both "in vitro" and "in vivo". Collectively the studies comprised breast cancer, prostate cancer, melanoma, glioblastoma, leukaemia, colon cancer and pancreatic cancer cell lines.
London, 13 May 2008
Lupus drug candidate IPP-201101 obtains trademark LUPUZOR TM
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today that it received approval of its trademark name LUPUZOR TM for its lead drug candidate for Lupus IPP-201101, by the US Patent and Trademark Office.
London, 8 May 2008
PRELIMINARY RESULTS ANNOUNCEMENT
for the year ended 31 December 2007
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce its preliminary results for the year ended 31 December 2007.
Key Highlights:
■
Recruitment of patients well underway with IPP-201101, drug candidate
for the treatment of Systemic Lupus Erythematosus, in pivotal Phase IIb
trial
■ Added a novel drug candidate to the pipeline, IPP-204106, for
cancer; rights obtained from Centre National de la Recherche
Scientifique (CNRS)
■
Discovery of a new lead candidate for inflammation, IPP-201007 from
internal proprietary chemical library
■
Consolidated cash balance at 31 December 2007 of approx £2.9 million.
London, 26 February 2008
First Lupus patients dosed with IPP-201101 in phase IIb study
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today announces today that the first patients have been dosed in its phase IIb trial of IPP-201101 for the treatment of Systemic Lupus Erythematosus. Assuming continued satisfactory patient recruitment with the trial, headline efficacy data are expected in the summer of 2008 as previously indicated.
London, 8 January 2008
ImmuPharma enters oncology with novel potential blockbuster drug for multiple cancer indications
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today that, as part of its ongoing research collaboration with the Centre National de la Recherche Scientifique ("CNRS"), France's scientific research institution, it has taken the rights for the worldwide development and commercialization of a novel drug candidate for cancer.
The molecule, code-named IPP-204106, has a dual mechanism of action, acting both in preventing angiogenesis as well as proliferation. IPP-204106 is a nucleolin antagonist, the lead molecule in a family of pseudopeptides designed to block the activity of a protein called nucleolin. Located essentially in the nucleus of normal cells where it is protected, nucleolin is much more abundant (often 100 times more) at the surface of the cells which are proliferating as well as the surface of active endothelial cells where it can be a target for antagonist peptides.
